Konstantinos Papamichail, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Monitoring | 42 | 2024 | 962 | 10.500 |
Why?
|
Inflammatory Bowel Diseases | 56 | 2024 | 2422 | 9.230 |
Why?
|
Gastrointestinal Agents | 37 | 2024 | 510 | 8.780 |
Why?
|
Crohn Disease | 45 | 2024 | 2279 | 8.220 |
Why?
|
Tumor Necrosis Factor-alpha | 31 | 2023 | 4352 | 3.770 |
Why?
|
Colitis, Ulcerative | 23 | 2024 | 1922 | 3.690 |
Why?
|
Biological Products | 15 | 2024 | 914 | 3.540 |
Why?
|
Remission Induction | 17 | 2024 | 2396 | 2.280 |
Why?
|
Azathioprine | 8 | 2022 | 354 | 1.910 |
Why?
|
Leukocyte L1 Antigen Complex | 3 | 2024 | 93 | 1.840 |
Why?
|
Rectal Fistula | 2 | 2024 | 75 | 1.450 |
Why?
|
Immunosuppressive Agents | 15 | 2024 | 4174 | 1.370 |
Why?
|
Antibodies, Monoclonal | 18 | 2024 | 9177 | 1.200 |
Why?
|
Mesalamine | 4 | 2018 | 135 | 1.190 |
Why?
|
Helicobacter pylori | 3 | 2019 | 377 | 1.140 |
Why?
|
Helicobacter Infections | 3 | 2019 | 388 | 1.130 |
Why?
|
Anti-Inflammatory Agents | 11 | 2024 | 1809 | 1.050 |
Why?
|
Tuberculin Test | 2 | 2015 | 206 | 0.950 |
Why?
|
Immunologic Factors | 7 | 2024 | 1589 | 0.910 |
Why?
|
Standard of Care | 4 | 2022 | 551 | 0.840 |
Why?
|
Latent Tuberculosis | 2 | 2015 | 224 | 0.820 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 6 | 2018 | 2273 | 0.810 |
Why?
|
Colonoscopy | 9 | 2020 | 1394 | 0.780 |
Why?
|
Heat-Shock Response | 4 | 2012 | 179 | 0.760 |
Why?
|
Serum | 3 | 2017 | 209 | 0.740 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2019 | 424 | 0.730 |
Why?
|
Capsule Endoscopy | 1 | 2021 | 100 | 0.720 |
Why?
|
Intestinal Fistula | 1 | 2021 | 142 | 0.700 |
Why?
|
Saccharomyces cerevisiae | 6 | 2019 | 2688 | 0.680 |
Why?
|
Interleukins | 1 | 2024 | 782 | 0.650 |
Why?
|
Calculi | 1 | 2019 | 48 | 0.650 |
Why?
|
Drug Tolerance | 2 | 2018 | 367 | 0.630 |
Why?
|
Proton-Translocating ATPases | 1 | 2019 | 112 | 0.630 |
Why?
|
Humans | 120 | 2024 | 761504 | 0.590 |
Why?
|
Thyroxine | 2 | 2019 | 666 | 0.560 |
Why?
|
Arthritis, Psoriatic | 1 | 2019 | 219 | 0.530 |
Why?
|
Wound Healing | 5 | 2024 | 2805 | 0.520 |
Why?
|
Intestinal Mucosa | 6 | 2021 | 3032 | 0.510 |
Why?
|
Colitis | 2 | 2022 | 1233 | 0.500 |
Why?
|
Feces | 3 | 2024 | 1497 | 0.500 |
Why?
|
Colectomy | 3 | 2017 | 688 | 0.480 |
Why?
|
Osteoporosis | 3 | 2019 | 1606 | 0.460 |
Why?
|
Treatment Outcome | 25 | 2024 | 64680 | 0.450 |
Why?
|
Antibodies | 3 | 2023 | 2418 | 0.450 |
Why?
|
Injections, Subcutaneous | 3 | 2024 | 681 | 0.430 |
Why?
|
Saccharomyces cerevisiae Proteins | 4 | 2019 | 1841 | 0.430 |
Why?
|
Cyclosporine | 2 | 2017 | 778 | 0.420 |
Why?
|
Histamine Antagonists | 1 | 2012 | 92 | 0.410 |
Why?
|
Granular Cell Tumor | 1 | 2012 | 48 | 0.400 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2020 | 10766 | 0.400 |
Why?
|
Cholangitis | 2 | 2018 | 111 | 0.400 |
Why?
|
Treatment Failure | 4 | 2019 | 2645 | 0.380 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1089 | 0.370 |
Why?
|
Adult | 40 | 2024 | 221177 | 0.370 |
Why?
|
Young Adult | 24 | 2024 | 59243 | 0.360 |
Why?
|
Colon | 2 | 2015 | 1792 | 0.360 |
Why?
|
Recurrence | 7 | 2023 | 8465 | 0.360 |
Why?
|
Mitogens | 1 | 2010 | 230 | 0.350 |
Why?
|
Thyroid Diseases | 2 | 2010 | 386 | 0.350 |
Why?
|
Salvage Therapy | 2 | 2017 | 1264 | 0.330 |
Why?
|
Middle Aged | 42 | 2024 | 220895 | 0.320 |
Why?
|
Necrosis | 2 | 2023 | 1611 | 0.320 |
Why?
|
Tumor Necrosis Factors | 2 | 2019 | 107 | 0.310 |
Why?
|
Peptides, Cyclic | 1 | 2010 | 392 | 0.300 |
Why?
|
Retrospective Studies | 24 | 2024 | 80636 | 0.300 |
Why?
|
Female | 50 | 2024 | 392644 | 0.290 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 983 | 0.290 |
Why?
|
Male | 45 | 2024 | 360804 | 0.290 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3810 | 0.290 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 312 | 0.280 |
Why?
|
Endocrine System Diseases | 1 | 2009 | 249 | 0.280 |
Why?
|
Drug Administration Schedule | 6 | 2018 | 4853 | 0.270 |
Why?
|
Delphi Technique | 2 | 2021 | 846 | 0.270 |
Why?
|
Fever of Unknown Origin | 1 | 2006 | 94 | 0.270 |
Why?
|
Thyrotropin | 1 | 2009 | 834 | 0.250 |
Why?
|
Bone Remodeling | 1 | 2009 | 581 | 0.250 |
Why?
|
Arthritis, Rheumatoid | 2 | 2019 | 3763 | 0.250 |
Why?
|
Arthritis | 1 | 2010 | 680 | 0.240 |
Why?
|
Thyroidectomy | 1 | 2009 | 907 | 0.220 |
Why?
|
Soft Tissue Neoplasms | 1 | 2012 | 1159 | 0.220 |
Why?
|
Integrins | 2 | 2019 | 834 | 0.210 |
Why?
|
Autoantibodies | 2 | 2021 | 2116 | 0.210 |
Why?
|
C-Reactive Protein | 4 | 2024 | 3826 | 0.210 |
Why?
|
Lymphocytes | 1 | 2010 | 2612 | 0.210 |
Why?
|
Methotrexate | 4 | 2022 | 1719 | 0.200 |
Why?
|
Withholding Treatment | 2 | 2018 | 617 | 0.200 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2244 | 0.180 |
Why?
|
Adolescent | 15 | 2023 | 88319 | 0.180 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2020 | 364 | 0.170 |
Why?
|
Histamine | 2 | 2014 | 499 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6484 | 0.170 |
Why?
|
Placebos | 1 | 2024 | 1667 | 0.170 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5486 | 0.170 |
Why?
|
Prospective Studies | 11 | 2023 | 54425 | 0.170 |
Why?
|
Adaptation, Physiological | 4 | 2012 | 1301 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.160 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 6935 | 0.160 |
Why?
|
Pharmacogenetics | 1 | 2023 | 675 | 0.160 |
Why?
|
Bone Density Conservation Agents | 2 | 2018 | 795 | 0.160 |
Why?
|
Belgium | 2 | 2017 | 118 | 0.160 |
Why?
|
Drug Substitution | 1 | 2021 | 290 | 0.150 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 291 | 0.150 |
Why?
|
Hepatitis B Core Antigens | 1 | 2018 | 90 | 0.150 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 613 | 0.150 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2016 | 874 | 0.150 |
Why?
|
Hepatitis B Antibodies | 1 | 2018 | 155 | 0.140 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3889 | 0.140 |
Why?
|
Causality | 1 | 2023 | 1242 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1702 | 0.140 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 294 | 0.140 |
Why?
|
Virus Activation | 1 | 2018 | 322 | 0.130 |
Why?
|
Postoperative Hemorrhage | 1 | 2019 | 415 | 0.130 |
Why?
|
Cycloheximide | 3 | 2012 | 343 | 0.130 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 134 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10209 | 0.130 |
Why?
|
Follow-Up Studies | 4 | 2018 | 39106 | 0.120 |
Why?
|
Hepatitis B virus | 1 | 2018 | 528 | 0.120 |
Why?
|
Comorbidity | 3 | 2019 | 10508 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2017 | 6310 | 0.120 |
Why?
|
Consensus | 2 | 2021 | 3123 | 0.120 |
Why?
|
Ranitidine | 1 | 2014 | 34 | 0.120 |
Why?
|
Prognosis | 5 | 2023 | 29625 | 0.120 |
Why?
|
Cytodiagnosis | 1 | 2017 | 447 | 0.110 |
Why?
|
Clostridium Infections | 1 | 2020 | 558 | 0.110 |
Why?
|
Abdominal Pain | 1 | 2019 | 1071 | 0.110 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 2012 | 397 | 0.110 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7390 | 0.100 |
Why?
|
Informed Consent | 1 | 2019 | 1008 | 0.100 |
Why?
|
Forecasting | 1 | 2022 | 2928 | 0.100 |
Why?
|
Ileum | 1 | 2015 | 557 | 0.100 |
Why?
|
Histamine H2 Antagonists | 1 | 2014 | 166 | 0.100 |
Why?
|
Gastritis | 1 | 2014 | 199 | 0.100 |
Why?
|
Risk Factors | 10 | 2019 | 74206 | 0.100 |
Why?
|
Pilot Projects | 3 | 2015 | 8631 | 0.100 |
Why?
|
Lymphoma | 1 | 2021 | 1901 | 0.100 |
Why?
|
Osteogenesis | 1 | 2018 | 1273 | 0.100 |
Why?
|
Microbial Viability | 1 | 2012 | 238 | 0.090 |
Why?
|
Heat-Shock Proteins | 2 | 2012 | 795 | 0.090 |
Why?
|
Time Factors | 8 | 2024 | 39967 | 0.090 |
Why?
|
Cohort Studies | 7 | 2020 | 41487 | 0.090 |
Why?
|
Documentation | 1 | 2017 | 897 | 0.090 |
Why?
|
Safety | 1 | 2016 | 1150 | 0.090 |
Why?
|
Guideline Adherence | 2 | 2020 | 2220 | 0.090 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 831 | 0.090 |
Why?
|
Meta-Analysis as Topic | 1 | 2016 | 1380 | 0.090 |
Why?
|
Lumbosacral Region | 1 | 2012 | 293 | 0.090 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2014 | 396 | 0.090 |
Why?
|
Child | 4 | 2023 | 80153 | 0.090 |
Why?
|
ROC Curve | 1 | 2018 | 3579 | 0.090 |
Why?
|
Hospitalization | 3 | 2019 | 10723 | 0.090 |
Why?
|
Secondary Prevention | 2 | 2018 | 1475 | 0.090 |
Why?
|
Carcinoma, Medullary | 1 | 2010 | 115 | 0.090 |
Why?
|
Rheumatic Diseases | 1 | 2017 | 649 | 0.080 |
Why?
|
Risk Assessment | 3 | 2023 | 23995 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2022 | 58976 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2319 | 0.080 |
Why?
|
Diphosphonates | 1 | 2014 | 636 | 0.080 |
Why?
|
Calcitonin | 1 | 2010 | 329 | 0.080 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3201 | 0.080 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7879 | 0.080 |
Why?
|
Cell Survival | 1 | 2019 | 5791 | 0.080 |
Why?
|
Immune System | 1 | 2014 | 796 | 0.080 |
Why?
|
Seroepidemiologic Studies | 1 | 2010 | 397 | 0.080 |
Why?
|
Premedication | 1 | 2009 | 246 | 0.080 |
Why?
|
Tuberculosis, Cardiovascular | 1 | 2008 | 8 | 0.080 |
Why?
|
Aged | 13 | 2022 | 169289 | 0.080 |
Why?
|
Protective Agents | 1 | 2009 | 150 | 0.080 |
Why?
|
Phosphorus | 1 | 2009 | 336 | 0.080 |
Why?
|
Protein Biosynthesis | 2 | 2012 | 2113 | 0.070 |
Why?
|
Imidazoles | 1 | 2014 | 1180 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26125 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 445 | 0.070 |
Why?
|
Hot Temperature | 3 | 2006 | 1440 | 0.070 |
Why?
|
Hyperparathyroidism | 1 | 2009 | 337 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 4016 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14666 | 0.070 |
Why?
|
Cholagogues and Choleretics | 1 | 2006 | 39 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2021 | 12341 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1183 | 0.070 |
Why?
|
Adenoma | 1 | 2017 | 2160 | 0.070 |
Why?
|
Ursodeoxycholic Acid | 1 | 2006 | 81 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.070 |
Why?
|
Anaphylaxis | 1 | 2014 | 757 | 0.070 |
Why?
|
Radiography | 1 | 2017 | 6965 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5492 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2850 | 0.070 |
Why?
|
gamma-Glutamyltransferase | 1 | 2006 | 144 | 0.070 |
Why?
|
Pericardial Effusion | 1 | 2008 | 247 | 0.060 |
Why?
|
Inflammation Mediators | 1 | 2014 | 1886 | 0.060 |
Why?
|
Collagen Type I | 1 | 2009 | 616 | 0.060 |
Why?
|
Education, Medical | 1 | 2017 | 1725 | 0.060 |
Why?
|
Ligands | 1 | 2012 | 3272 | 0.060 |
Why?
|
Endoscopy | 1 | 2015 | 1851 | 0.060 |
Why?
|
Hydrocortisone | 2 | 2014 | 1819 | 0.060 |
Why?
|
Postoperative Care | 1 | 2012 | 1468 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2015 | 1998 | 0.060 |
Why?
|
Benzoquinones | 1 | 2006 | 198 | 0.060 |
Why?
|
Methylprednisolone | 1 | 2006 | 385 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2017 | 3060 | 0.060 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 917 | 0.060 |
Why?
|
Lymph Nodes | 2 | 2021 | 3466 | 0.060 |
Why?
|
Prednisolone | 1 | 2006 | 326 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1833 | 0.060 |
Why?
|
Camptothecin | 2 | 2006 | 591 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2011 | 768 | 0.060 |
Why?
|
Hypothyroidism | 1 | 2009 | 668 | 0.060 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 1008 | 0.060 |
Why?
|
Lactams, Macrocyclic | 1 | 2006 | 318 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2508 | 0.060 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 785 | 0.060 |
Why?
|
Polysaccharides | 1 | 2010 | 1014 | 0.060 |
Why?
|
Alkaline Phosphatase | 1 | 2006 | 864 | 0.050 |
Why?
|
Biological Therapy | 1 | 2024 | 141 | 0.050 |
Why?
|
Parathyroid Hormone | 1 | 2009 | 1803 | 0.050 |
Why?
|
Piperazines | 1 | 2012 | 2523 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 621 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 868 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 3164 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15266 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11742 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12463 | 0.050 |
Why?
|
Influenza, Human | 1 | 2011 | 1521 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1372 | 0.040 |
Why?
|
Postoperative Complications | 2 | 2019 | 15631 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 4249 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2022 | 779 | 0.040 |
Why?
|
Laxatives | 1 | 2020 | 92 | 0.040 |
Why?
|
Saccharomyces | 1 | 2000 | 63 | 0.040 |
Why?
|
Molybdenum | 1 | 1999 | 46 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4591 | 0.040 |
Why?
|
Immunotherapy | 1 | 2015 | 4652 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6534 | 0.040 |
Why?
|
Mass Screening | 1 | 2015 | 5428 | 0.040 |
Why?
|
Thyroid Neoplasms | 2 | 2010 | 2332 | 0.040 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2019 | 293 | 0.040 |
Why?
|
Estradiol | 1 | 2006 | 1937 | 0.040 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2759 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 1405 | 0.040 |
Why?
|
Peptides | 1 | 2009 | 4358 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15732 | 0.040 |
Why?
|
Private Practice | 1 | 2017 | 153 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
Calcium | 1 | 2009 | 5722 | 0.030 |
Why?
|
Preoperative Care | 1 | 2024 | 2242 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1078 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2015 | 69 | 0.030 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2019 | 464 | 0.030 |
Why?
|
Colonic Polyps | 1 | 2019 | 554 | 0.030 |
Why?
|
Acute-Phase Reaction | 1 | 2014 | 91 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 413 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29874 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3305 | 0.030 |
Why?
|
Complement C1r | 1 | 2013 | 5 | 0.030 |
Why?
|
beta 2-Glycoprotein I | 1 | 2013 | 28 | 0.030 |
Why?
|
Resistin | 1 | 2014 | 172 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1722 | 0.030 |
Why?
|
Plasminogen | 1 | 2013 | 144 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13255 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2017 | 756 | 0.030 |
Why?
|
Clusterin | 1 | 2013 | 71 | 0.030 |
Why?
|
Complement C4b | 1 | 2013 | 126 | 0.030 |
Why?
|
Up-Regulation | 2 | 2013 | 4124 | 0.030 |
Why?
|
Medical Records | 1 | 2017 | 1408 | 0.020 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 131 | 0.020 |
Why?
|
Transferrin | 1 | 2013 | 283 | 0.020 |
Why?
|
Cross Reactions | 1 | 2014 | 817 | 0.020 |
Why?
|
Apolipoprotein A-I | 1 | 2013 | 299 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2015 | 983 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1638 | 0.020 |
Why?
|
United States | 1 | 2019 | 72334 | 0.020 |
Why?
|
DNA, Viral | 1 | 2018 | 2202 | 0.020 |
Why?
|
Disease Progression | 2 | 2023 | 13506 | 0.020 |
Why?
|
Fellowships and Scholarships | 1 | 2019 | 1117 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5840 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2568 | 0.020 |
Why?
|
Prescription Drugs | 1 | 2017 | 631 | 0.020 |
Why?
|
Health Services Research | 1 | 2017 | 1812 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36426 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2013 | 853 | 0.020 |
Why?
|
Greece | 1 | 2010 | 340 | 0.020 |
Why?
|
Chaperonin 60 | 1 | 2009 | 97 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 2009 | 330 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2901 | 0.020 |
Why?
|
Adiponectin | 1 | 2014 | 1113 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
Apolipoproteins E | 1 | 2013 | 1444 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.020 |
Why?
|
Obesity | 1 | 2009 | 12947 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2016 | 2161 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2010 | 339 | 0.020 |
Why?
|
Suramin | 1 | 2006 | 34 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12059 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6240 | 0.020 |
Why?
|
Leptin | 1 | 2014 | 1597 | 0.020 |
Why?
|
Tubulin | 1 | 2009 | 693 | 0.020 |
Why?
|
Vincristine | 1 | 2008 | 1036 | 0.020 |
Why?
|
Glycoproteins | 1 | 2013 | 2203 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3551 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9280 | 0.010 |
Why?
|
Fatigue | 1 | 2011 | 1552 | 0.010 |
Why?
|
Fever | 1 | 2011 | 1618 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2014 | 3208 | 0.010 |
Why?
|
Headache | 1 | 2011 | 1256 | 0.010 |
Why?
|
Prednisone | 1 | 2008 | 1563 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10773 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18395 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15842 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2010 | 2915 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2008 | 2218 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12690 | 0.010 |
Why?
|
Doxorubicin | 1 | 2008 | 2224 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8224 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2014 | 3963 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2008 | 1375 | 0.010 |
Why?
|
Proteomics | 1 | 2013 | 3849 | 0.010 |
Why?
|
Mitomycin | 1 | 2000 | 263 | 0.010 |
Why?
|
Bleomycin | 1 | 2000 | 494 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21353 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2000 | 13639 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11121 | 0.010 |
Why?
|
Fluorouracil | 1 | 2000 | 1641 | 0.010 |
Why?
|
Antifungal Agents | 1 | 1999 | 752 | 0.010 |
Why?
|
Cisplatin | 1 | 2000 | 1651 | 0.010 |
Why?
|
Smoking | 1 | 2010 | 9053 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168459 | 0.000 |
Why?
|